MedImpact Healthcare Systems, Inc., 10181 Scripps Gateway Ct., San Diego, CA 92131.
J Manag Care Spec Pharm. 2014 Dec;20(12):1193-203. doi: 10.18553/jmcp.2014.20.12.1193.
The Centers for Medicare Medicaid Services (CMS) Plan Quality and Performance Program, or Star Ratings Program, allows Medicare beneficiaries to compare quality of care among available Medicare Advantage prescription drug (MA-PD) plans and stand-alone prescription drug plans (PDPs). Health plans have increased intervention efforts and applied existing care management infrastructure as an approach to improving member medication adherence and subsequent Part D star rating performance. Independent Care Health Plan (iCare), an MA-PD plan; MedImpact Healthcare Systems, Inc. (MedImpact), a pharmacy benefits manager; and US MED, a mail order pharmacy, partnered to engage and enroll iCare's dual-eligible special needs population in an intervention designed to improve patient medication adherence and health plan performance for 3 Part D patient safety outcome measures: Medication Adherence for Oral Diabetes Medications (ODM), Medication Adherence for Hypertension (HTN), and Medication Adherence for Cholesterol (CHOL).
To (a) assess the effectiveness of a coordinated member-directed medication adherence intervention and (b) determine the overall impact of the intervention on adherence rates and CMS Part D star rating adherence measures.
Administrative pharmacy claims and health plan eligibility data from MedImpact's databases were used to identify members using 3 target medication classes. Adherence was estimated by the proportion of days covered (PDC) for all members. Those members considered at high risk for nonadherence were prioritized for care management services. Risk factors were based on members' use of more than 1 target medication class, newly started therapy, and suboptimal adherence (PDC less than 80%) in the most recent 6-month period. Data files listing member adherence rates and contact information were formatted and loaded monthly into iCare's care management system, which triggered an alert for care coordinators to counsel members on the importance of adherence and offer the members an option for monthly 30-day supply medication delivery via US MED. Member adherence rates were calculated 9 months pre- and postimplementation for all members and adjusted by length of member enrollment based on CMS technical specifications. Regression analysis assessed pre-post changes in rates comparing 2 intervention groups: (1) members receiving iCare counseling only (iCare-only) and (2) members receiving counseling and medication delivery (iCare + US MED). To evaluate the overall impact of the intervention, iCare's adherence rates and iCare's measure-specific star ratings for the 2011 and 2012 calendar years (CMS measurement years) were compared with the national MA-PD plan contract average and with a health plan similar in member characteristics but without adherence intervention exposure.
A total of 2,700 members were initially targeted for referral to iCare care management and US MED customer service specialist teams. Between April 2012 (implementation date) and January 2013, 1,302 (48.2%) members enrolled in the US MED component of the intervention. Seventy-six percent of identified members were nonadherent (PDC less than 80%) to 1 of the 3 target medication classes, and 32% of members were nonadherent to more than 1 target medication class. Pre-post absolute average adherence rates increased for the iCare-only group (ODM = 15.1, HTN = 10.1, CHOL = 13.6) and the iCare-US MED group (ODM = 30.9, HTN = 25.5, CHOL = 29.4). From 2011 to 2012, iCare adherence rates increased by absolute differences of 15.2, 9.2, and 10.1 percentage points for ODM, HTN, and CHOL measures, respectively, compared with the average MA-PD plan contract differences (1.1, 2.1, and 2.5) and the comparator health plan differences (-2.7, -1.4, and -4.1). Increases in iCare's adherence rates were associated with significant increases in iCare's 2014 adherence measure star ratings (1 star to 3 stars for ODM and CHOL, 1 star to 2 stars for HTN), which contributed to increases in the Drug Plan Quality Improvement measure (2 stars to 4 stars) and iCare's overall Part D star rating (3 to 3.5 stars).
Members in this MA-PD plan dual-eligible population benefited from multiple points of contact to achieve increased adherence. Health plans can use network pharmacies, care management staff, and their pharmacy benefits managers to collaborate and implement interventions aimed to improve members' adherence to targeted maintenance medications and overall health plan quality performance and star ratings.
医疗保险和医疗补助服务中心(CMS)计划质量和绩效计划(或星级评定计划)允许医疗保险受益人比较可用的医疗保险优势处方药(MA-PD)计划和独立处方药计划(PDP)之间的护理质量。为了提高成员的药物依从性并提高随后的部分 D 星级评定绩效,健康计划已经增加了干预措施并应用了现有的护理管理基础设施。独立护理健康计划(iCare)是一个 MA-PD 计划;MedImpact Healthcare Systems,Inc.(MedImpact),一家药房福利经理;和美国医疗保健,一家邮购药房,合作参与并招募 iCare 的双重资格特殊需要人群,以实施一项干预措施,旨在提高患者对口服糖尿病药物(ODM)、高血压(HTN)和胆固醇(CHOL)等三种部分 D 患者安全结果措施的药物依从性。
(a)评估协调成员导向的药物依从性干预措施的有效性;(b)确定干预措施对依从率和 CMS 部分 D 星级评定依从性措施的总体影响。
从 MedImpact 的数据库中使用行政药房理赔和健康计划资格数据来识别使用 3 种目标药物类别的成员。通过所有成员的比例天数覆盖(PDC)来估计依从性。那些被认为有非依从性高风险的成员被优先考虑进行护理管理服务。风险因素基于成员对超过 1 种目标药物类别的使用、新开始的治疗和最近 6 个月的次优依从性(PDC<80%)。列出成员依从率和联系信息的数据文件被格式化并每月加载到 iCare 的护理管理系统中,这会触发护理协调员的警报,提醒成员遵守药物依从性的重要性,并为成员提供通过美国医疗保健每月 30 天供应药物的选择。在所有成员中计算了实施前后 9 个月的成员依从率,并根据 CMS 技术规范,根据成员注册的长度进行了调整。回归分析比较了 2 个干预组的比率变化:(1)仅接受 iCare 咨询的成员(iCare-only);(2)接受咨询和药物交付的成员(iCare+US MED)。为了评估干预的总体影响,将 iCare 在 2011 年和 2012 日历年(CMS 测量年份)的依从率和特定措施星级评定与全国 MA-PD 计划合同平均值以及成员特征相似但没有依从性干预暴露的健康计划进行了比较。
最初有 2700 名成员被确定为转介给 iCare 护理管理和美国医疗保健客户服务专家团队。2012 年 4 月(实施日期)至 2013 年 1 月期间,有 1302 名(48.2%)成员参加了干预措施的美国医疗保健部分。确定的成员中有 76%(PDC<80%)对 3 种目标药物类别的 1 种药物不依从,32%的成员对超过 1 种目标药物类别的药物不依从。iCare-only 组(ODM=15.1,HTN=10.1,CHOL=13.6)和 iCare-US MED 组(ODM=30.9,HTN=25.5,CHOL=29.4)的前后绝对平均依从率均有所增加。与 MA-PD 计划合同差异的平均差异(1.1、2.1 和 2.5)和比较健康计划差异(-2.7、-1.4 和-4.1)相比,2011 年至 2012 年,iCare 的依从率增加了 15.2、9.2 和 10.1 个百分点,分别用于 ODM、HTN 和 CHOL 措施,并且 iCare 的 2014 年依从性测量星级评定也有所增加(ODM 和 CHOL 的 1 星至 3 星,HTN 的 1 星至 2 星),这导致了药物计划质量改进措施(从 2 星到 4 星)和 iCare 的整体部分 D 星级评定(从 3 星到 3.5 星)的增加。
该 MA-PD 计划双重合格人群中的成员受益于多次接触以提高依从性。健康计划可以使用网络药房、护理管理人员和他们的药房福利经理进行合作,并实施旨在提高成员对目标维持药物的依从性和整体健康计划质量绩效和星级评定的干预措施。